Doctors have confirmed that this season has seen an unusual spike in both viral as well as bacterial infections. Pollution, ...
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Doctors may one day save lives with oxygen delivered through the rectum instead of the lungs. A first trial shows the body ...
A chilling warning has been issued to those who use wood burners or coal fires in their homes, as a new study suggests they ...
This afternoon (October 27), in the provinces and cities of the Central region, it continued to rain heavily, in Hue and Da ...
InvestorsHub on MSN
BridgeBio stock soars after breakthrough Phase 3 data for muscular dystrophy treatment
BridgeBio Pharma (NASDAQ:BBIO) shares surged 15% on Monday after the company announced highly positive Phase 3 results for ...
The ubiquitous particles are probably impossible to eliminate, but there are strategies for hospital systems to reduce their ...
6don MSNOpinion
Can Utah’s governor actually save the Great Salt Lake?
No imperiled saline lake anywhere in the world has been rescued. Gov. Spencer Cox is confident Utah will be the first to ...
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). | In a mixed interim data drop, Arcturus ...
Anyone who has a wood burner or coal fire in their homes has been given a chilling warning - with a new study claiming it ...
Investing.com -- BridgeBio Pharma (NASDAQ:BBIO) stock rose 15% after reporting positive Phase 3 results for its small molecule BBP-418 in the treatment of limb-girdle muscular dystrophy type 2I/R9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback